Psychosocial Risks in Liver Transplant Recipients

Completed

Conditions studied: End Stage Liver Disease

In brief

A retrospective chart review in which the information in the standard psychosocial evaluations done pre-transplant for liver transplant recipients will be coded, recorded, and correlated with posttransplant outcomes of the same recipients. Evaluated outcomes include rejection episodes and adherence to tacrolimus, calculated through the MLVI (Medication Level Variability Index). The researchers will evaluate the degree to which both single elements in the evaluation as well as a cumulative score derived by a structured review of the chart using the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) model can predict posttransplant outcomes.

Key facts

Study ID

NCT02826460

Run by

Icahn School of Medicine at Mount Sinai

People needed

200

Starts

2014-11-01

Expected to finish

2016-06-01

Last updated by the study team

2016-07-11

Who can join

Age: 18 and older, up to 74. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Received a liver transplant in the year 2012 or earlier
• Received Tacrolimus
• Had at least 3 Tacrolimus blood tests
• Received their transplant at RMTI

You may not qualify if…

• Patients who received more than 1 solid organ transplant
• Patients who were not prescribed Tacrolimus
• Patients who died within the first year after transplant
• Patients with cognitive impairment

Where it is running

• Icahn School of Medicine at Mount Sinia — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.